Simultaneous spectrophotometric determination of phenilpropanolamine HCL, caffeine and diazepam in tablets

被引:22
作者
Ferreyra, CF [1 ]
Ortiz, CS [1 ]
机构
[1] Natl Univ Cordoba, Fac Ciencias Quim, Dept Farmacia, RA-5000 Cordoba, Argentina
关键词
analysis; HPLC; spectrophometric; phenilpropanolamine hydrochloride; caffeine; diazepam;
D O I
10.1016/S0731-7085(02)00130-9
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A rapid, reliable and specitic UV spectrophotometric method was developed to determine Phenilpropanolamine Hydrochloride (I), Caffeine (II) and Diazepam (III) formulated in tablets. This method was validated and compared with a liquid chromatography (LC) procedure used for the simultaneous quantitative analysis of the drugs. The established linearity ranges by both methods for compounds I, II and III were 0.36-0.88, 0.012-0.028 and 0.036-0.084 mg/ml, respectively. The correlation coefficients by HPLC were r(I)(2) = 0.997, r(II)(2) = 0.999, r(III)(2) = 0.999 and by the UV spectrophotometric method were r(I)(2) = 0. 998, r(II)(2) = 0 996, r(III)(2) = 0.999. LC and UV methods showed precision and accuracy. As regards precision, LC showed CV values range of 0.2-0.9 and UV 0. 15-0.72. On the other hand, accuracy was obtained with CV values range of 0.1-1.8 and 0.32-1.11 for LC and UV, respectively. The recoveries of I, II and III were > 98.04% for both methods over the linear range. The UV and HPLC methods have been successfully used to determine the I, II and III content in tablets of different origin. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:811 / 818
页数:8
相关论文
共 11 条
[1]  
[Anonymous], CHROMATOGRAPHIC ANAL
[2]   Analysis of multicomponent formulations containing phenylpropanolamine hydrochloride, caffeine and diazepam by using LC [J].
Ferreyra, C ;
Ortiz, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2001, 25 (3-4) :493-499
[3]  
Florey K, 1986, ANAL PROFILES DRUG S, P71
[4]  
FLOREY K, 1999, ANAL PROFILES DRUG S, P80
[5]  
LUNN G, 1997, HPLC METHODS PHARM A
[6]  
MICHAEL JKT, 1996, ULTRAVIOLET VISIBLE
[7]  
RILEY CM, 1996, PROGR PHARM BIOMEDIC, V3, pCH2
[8]  
Swartz MichaelE., 1997, ANAL METHOD DEV VALI
[9]  
*US DEP HHS, 1996, ICH Q 2B VALIDATION
[10]  
*WHO, 1979, INT PHARM, P85